Kiniksa Pharmaceuticals, Ltd. (KNSA)
NASDAQ: KNSA · IEX Real-Time Price · USD
19.83
+0.06 (0.30%)
May 20, 2024, 1:52 PM EDT - Market open
Kiniksa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for KNSA stock have an average target of 30.2, with a low estimate of 25 and a high estimate of 34. The average target predicts an increase of 52.29% from the current stock price of 19.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KNSA stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 2 | 2 | 2 | 2 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Initiates $34 | Buy | Initiates | $34 | +71.46% | May 3, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $26 → $30 | Buy | Maintains | $26 → $30 | +51.29% | May 1, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $25 → $30 | Buy | Maintains | $25 → $30 | +51.29% | Apr 24, 2024 |
| Wedbush | Wedbush | Buy Maintains $23 → $25 | Buy | Maintains | $23 → $25 | +26.07% | Jan 2, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $22 → $32 | Strong Buy | Maintains | $22 → $32 | +61.37% | Jul 26, 2023 |
Financial Forecast
Revenue This Year
390.59M
from 270.26M
Increased by 44.52%
Revenue Next Year
522.63M
from 390.59M
Increased by 33.81%
EPS This Year
-0.17
from 0.20
EPS Next Year
0.05
from -0.17
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 443.5M | 633.9M | 695.2M | 829.5M | 945.0M |
| Avg | 390.6M | 522.6M | 628.7M | 802.4M | 699.3M |
| Low | 359.0M | 436.1M | 541.9M | 767.6M | 461.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 64.1% | 62.3% | 33.0% | 31.9% | 17.8% |
| Avg | 44.5% | 33.8% | 20.3% | 27.6% | -12.8% |
| Low | 32.8% | 11.7% | 3.7% | 22.1% | -42.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 0.79 | 1.08 | 0.42 | 1.94 |
| Avg | -0.17 | 0.05 | 0.09 | 1.89 |
| Low | -0.66 | -0.64 | -0.23 | 1.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 293.8% | - | 782.3% | 2,140.5% |
| Avg | - | - | 82.1% | 2,076.5% |
| Low | - | - | - | 1,991.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.